Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H37N5O2 |
Molecular Weight | 451.6043 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=CNC4=C3C(=CC=C4)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC
InChI
InChIKey=KORNTPPJEAJQIU-KJXAQDMKSA-N
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
Molecular Formula | C26H37N5O2 |
Molecular Weight | 451.6043 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/dosage/cabergoline.html
http://www.wikidoc.org/index.php/Cabergoline
http://www.rxlist.com/dostinex-drug.htm
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/dosage/cabergoline.html
http://www.wikidoc.org/index.php/Cabergoline
http://www.rxlist.com/dostinex-drug.htm
Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. It is FDA approved for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Common adverse reactions include constipation, nausea, dizziness, headache and fatigue. Cabergoline should not be administered concurrently with D-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18691132 |
1.5 nM [Ki] | ||
Target ID: CHEMBL2095169 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18691132 |
0.5 nM [Ki] | ||
Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18691132 |
1.2 nM [Ki] | ||
Target ID: CHEMBL217 |
0.69 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CABERGOLINE Approved UseCabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Launch Date1.13581438E12 |
|||
Primary | CABERGOLINE Approved UseCabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Launch Date1.13581438E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.3 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7883840 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.3 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7883840 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
67 ng/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7883840 |
1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12952 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7883840 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1884 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7883840 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2546 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7883840 |
1.5 mg single, oral dose: 1.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
68.54 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7884663 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
CABERGOLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60% |
unknown, unknown |
CABERGOLINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Co-administed with:: L-dopa, po(370.6 mg) Sources: Page: p.18, p.19, p.22 |
unhealthy, 41.0–73.5 n = 34 Health Status: unhealthy Condition: Parkinson’s disease Age Group: 41.0–73.5 Sex: M+F Population Size: 34 Sources: Page: p.18, p.19, p.22 |
|
2 mg 1 times / day multiple, oral (min) Overdose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Parkinson’s disease Sources: Page: p.4 |
Other AEs: Cardiac valvulopathy... Other AEs: Cardiac valvulopathy Sources: Page: p.4 |
0.5 mg 2 times / week multiple, oral Recommended Dose: 0.5 mg, 2 times / week Route: oral Route: multiple Dose: 0.5 mg, 2 times / week Sources: Page: p.9 |
unhealthy n = 221 Health Status: unhealthy Condition: Hyperprolactinemic disorders Population Size: 221 Sources: Page: p.9 |
Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (1.4%) Sources: Page: p.9Nausea (0.9%) Vomiting (0.9%) |
1 mg 2 times / week multiple, oral (max) Recommended Dose: 1 mg, 2 times / week Route: oral Route: multiple Dose: 1 mg, 2 times / week Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Hyperprolactinemic disorders Sources: Page: p.4 |
Disc. AE: Pleural effusion, Pulmonary fibrosis... Other AEs: Cardiac valvulopathy, Pericardial fibrosis... AEs leading to discontinuation/dose reduction: Pleural effusion Other AEs:Pulmonary fibrosis Cardiac valvulopathy Sources: Page: p.4Pericardial fibrosis Retroperitoneal fibrosis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiac valvulopathy | 2 mg 1 times / day multiple, oral (min) Overdose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Parkinson’s disease Sources: Page: p.4 |
|
Nausea | 0.9% Disc. AE |
0.5 mg 2 times / week multiple, oral Recommended Dose: 0.5 mg, 2 times / week Route: oral Route: multiple Dose: 0.5 mg, 2 times / week Sources: Page: p.9 |
unhealthy n = 221 Health Status: unhealthy Condition: Hyperprolactinemic disorders Population Size: 221 Sources: Page: p.9 |
Vomiting | 0.9% Disc. AE |
0.5 mg 2 times / week multiple, oral Recommended Dose: 0.5 mg, 2 times / week Route: oral Route: multiple Dose: 0.5 mg, 2 times / week Sources: Page: p.9 |
unhealthy n = 221 Health Status: unhealthy Condition: Hyperprolactinemic disorders Population Size: 221 Sources: Page: p.9 |
Headache | 1.4% Disc. AE |
0.5 mg 2 times / week multiple, oral Recommended Dose: 0.5 mg, 2 times / week Route: oral Route: multiple Dose: 0.5 mg, 2 times / week Sources: Page: p.9 |
unhealthy n = 221 Health Status: unhealthy Condition: Hyperprolactinemic disorders Population Size: 221 Sources: Page: p.9 |
Cardiac valvulopathy | 1 mg 2 times / week multiple, oral (max) Recommended Dose: 1 mg, 2 times / week Route: oral Route: multiple Dose: 1 mg, 2 times / week Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Hyperprolactinemic disorders Sources: Page: p.4 |
|
Pericardial fibrosis | 1 mg 2 times / week multiple, oral (max) Recommended Dose: 1 mg, 2 times / week Route: oral Route: multiple Dose: 1 mg, 2 times / week Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Hyperprolactinemic disorders Sources: Page: p.4 |
|
Retroperitoneal fibrosis | 1 mg 2 times / week multiple, oral (max) Recommended Dose: 1 mg, 2 times / week Route: oral Route: multiple Dose: 1 mg, 2 times / week Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Hyperprolactinemic disorders Sources: Page: p.4 |
|
Pleural effusion | Disc. AE | 1 mg 2 times / week multiple, oral (max) Recommended Dose: 1 mg, 2 times / week Route: oral Route: multiple Dose: 1 mg, 2 times / week Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Hyperprolactinemic disorders Sources: Page: p.4 |
Pulmonary fibrosis | Disc. AE | 1 mg 2 times / week multiple, oral (max) Recommended Dose: 1 mg, 2 times / week Route: oral Route: multiple Dose: 1 mg, 2 times / week Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Hyperprolactinemic disorders Sources: Page: p.4 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/31183987/ Page: - |
likely |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes | yes (co-administration study) Comment: n healthy male volunteers, the mean of Cmax and AUC of cabergoline increased around 2.7 times by coadministration of clarithromycin. Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. | 2000 Dec |
|
Prolactinomas in children and adolescents--consequences in adult life. | 2001 |
|
[Dostinex - the most effective medicine for inhibition of postpartal lactation]. | 2001 |
|
Clinical data on restless legs syndrome: a dose-finding study with cabergoline. | 2001 |
|
Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. | 2001 |
|
Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy. | 2001 |
|
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease. | 2001 |
|
Cabergoline for levodopa-induced complications in Parkinson's disease. | 2001 |
|
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. | 2001 |
|
Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. | 2001 Aug |
|
Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats. | 2001 Aug |
|
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. | 2001 Feb |
|
Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. | 2001 Feb |
|
Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline. | 2001 Feb |
|
ACTH silent adenoma shrinking under cabergoline. | 2001 Jan |
|
Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma. | 2001 Jan |
|
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. | 2001 Jan |
|
Clusterlike headache as first manifestation of a prolactinoma. | 2001 Jul-Aug |
|
Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. | 2001 Mar |
|
Polycystic ovary syndrome and hyperprolactinemia. | 2001 Mar |
|
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches. | 2001 May 31 |
|
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. | 2001 Nov |
|
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. | 2001 Nov |
|
Determination of cabergoline by electrospray ionization tandem mass spectrometry: picogram detection via column focusing sample introduction. | 2001 Oct 15 |
|
[A case of elderly onset Parkinson's disease complicated by dropped head syndrome]. | 2001 Sep |
|
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. | 2001 Sep |
|
Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia. | 2001 Sep |
|
Pregnancy termination in the bitch and queen. | 2002 Aug |
|
Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. | 2002 Dec |
|
Alopecia induced by dopamine agonists. | 2002 Dec 24 |
|
Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? | 2002 Jan |
|
Gateways to clinical trials. | 2002 Jul-Aug |
|
Dopamine receptor agonists for treating prolactinomas. | 2002 Jun |
|
[Novel pharmacologic therapies in acromegaly]. | 2002 May 12 |
|
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. | 2002 Nov |
|
Effect of cabergoline on thyroid function in hyperprolactinaemia. | 2002 Nov |
|
Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data. | 2002 Nov 30 |
|
Pregnancy outcome after cabergoline treatment in early weeks of gestation. | 2002 Nov-Dec |
|
An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease. | 2002 Oct |
|
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma. | 2002 Oct |
|
A practical synthesis of cabergoline. | 2002 Oct 4 |
|
Radioimmunoassay of prolactin for the meerkat (Suricata suricatta), a cooperatively breeding carnivore. | 2003 Feb 1 |
|
[Efficacy of cabergoline in the treatment of macroprolactinoma]. | 2003 Jan 18 |
Sample Use Guides
The recommended dosage for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12464354
Tert-butylhydroperoxide caused a 42+/-4% neuronal death, which was prevented by cabergoline (2 h before) in a concentration-dependent manner (EC(50): 1.24 microM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 21:51:56 UTC 2023
by
admin
on
Thu Jul 06 21:51:56 UTC 2023
|
Record UNII |
LL60K9J05T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
NCI_THESAURUS |
C38149
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
WHO-VATC |
QG02CB03
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
WHO-ATC |
N04BC06
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
NDF-RT |
N0000007618
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
LIVERTOX |
135
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
WHO-VATC |
QN04BC06
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
NDF-RT |
N0000175827
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
WHO-ATC |
G02CB03
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
NDF-RT |
N0000007618
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
VELACTIS [SUSPENDED]
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201087
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
460
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
C047047
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
CABERGOLINE
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
81409-90-7
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
37
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
C47428
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
5860
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
100000092143
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
II-10
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
DTXSID6022719
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
47579
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | RxNorm | ||
|
3286
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
1084306
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
54746
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
Cabergoline
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
SUB06041MIG
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
DB00248
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
LL60K9J05T
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
LL60K9J05T
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | |||
|
M2876
Created by
admin on Thu Jul 06 21:51:58 UTC 2023 , Edited by admin on Thu Jul 06 21:51:58 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
7% in urine
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
41% in urine
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||